Join us in-person in Cambridge MA at PSC-Derived Therapies Symposium where Evotec is a gold sponsor. Learn more about our involvement in the event below.
Evotec at PSC-Derived Therapies Symposium
Presentation
Creating competitive and safe gene edited allogenic iPSC-derived cell therapy products for regenerative medicine and oncology
Speaker: Matthias Austen, SVP Cell Therapy, iPSC Cell Therapy
Session: Next Generation Cell Therapies Pipeline II
Date and time: 12 Dec 2025, 3:40PM - 4:00PM EST
Poster Presentations
Cloaked RPE cell replacement: Enhancing survival and immune evasion in retinal therapy (poster no. 125)
Presenter: Joana Ribeiro, Research Scientist, iPSC Cell Therapy
Date and time: 11 Dec 2025; 5:15PM - 6:15PM EST
Our poster presents an approach to improve RPE cell survival and immune evasion in retinal therapy. Retinal degeneration leads to irreversible blindness, and effective restoration often requires replacing both RPE and photoreceptor cells. While RPE replacement has shown safety in clinical studies, long-term survival and large-scale manufacturing remain major challenges. We describe a GMP-compliant process to produce cryopreservable, highly pure RPE cells and apply immune-shielding technology to reduce T-cell and NK-cell mediated rejection. Edited iPSC-derived RPE cells were compared directly with unedited controls to assess immune protection and functionality.
Enabling neuroretinal repair. Cost-efficient and GMP-compliant cell therapy strategies for vision restoration (poster No. 166)
Presenter: Joana Ribeiro, Research Scientist, iPSC Cell Therapy
Date and time: 11 Dec 2025; 6:15PM - 7:15PM EST
Our poster describes strategies to overcome key challenges in neuroretinal repair. Vision loss from age-related and inherited diseases results from irreversible degeneration, underscoring the need for cell-based restoration. Current drug and gene therapies fail at advanced stages due to depleted target cells, while cell therapy approaches face low yield, lengthy protocols, and high costs. We present a GMP-compliant process to generate multiple retinal cell types, addressing manufacturing bottlenecks and enabling scalable, cost-efficient cell therapy for vision restoration.
